Journal of Cancer Chemotherapy

Editorial Board

The Editorial Board of the journal is responsible for maintaining the quality and integrity of the journal's content. The board members are experts in their respective fields and play a crucial role in the peer review process, ensuring that all articles published meet the highest academic standards.

The Editorial Board is committed to upholding the principles of academic excellence, transparency, and ethical publishing practices. They work closely with authors, reviewers, and the editorial team to facilitate a smooth publication process.

Editor-in-Chief

Mohanad Diab

Mohanad Diab MBBS, MD

Editor-in-Chief

Department: Department of Oncology

Affiliation: Oncology, Karolinska University, Stockholm

Designation: Director of Oncology Hematology Services

Country: sweden

I worked as a consultant medical Oncologist since 2008 in the West Gotland Region in Sweden which has two main Oncology departments (I was the Key person in Establishing and leading the oncology clinic team in the second Oncology Clinic) those two hospitals are far of each others about 60 km and serve about 160 thousand inhabitant with a capacity of 525 beds for the first hospital and 300 bed for the second hospital.

The Oncology departments consist of ambulatory section (cancer patients with acute cases). Chemotherapy section (patients who under ongoing chemotherapy treatment) and out patients’ clinic. (Curative and Palliative patients). I lead and organize the Oncology department at the second hospital (skene Hospital).

I had my own Oncology studies as a primary investigator and I participate in many studies at our Oncology department for different Tumor diagnosis

Primary investigator in LETET , RALF, PARIS, RADIUM, PICASOS, ELITE Studies.

Currently I am a primary investigator in several international, regional and local studies.

Since may 2014 working as a Consultant medical Oncologist at NMC specialty hospital in Abu Dhabi, I built up the Oncology clinic at NMC hospital from Zero where, all chemotherapy protocols according to highest international standards. Number of my patients in there increased in a very fast way and the one room clinic turned to a full floor in 2 years.

I also established the oncology clinic at royal nmc hospital.

Since I joined NMC I built up a full team for tumor board consist of Onc-surgeon, Onco-radiologist and onco-pathologist and created a tumor board team. I have made those teams in all nmc hospitals.

In 2017 I became the Chair of Oncology line in NMC group until January 2022.

February 2022 Director of Oncology of Abu Dhabi Burjeel and head of Oncology department of Burjeel hospital until October 2024.

Director of Oncology/Hematology Services at Mediclinic Hospital.

Participated in more than 100 publications related to Oncology and Haematology. Details available upon request.

Rabindra Nath Das

Rabindra Nath Das Ph.D

Editor-in-Chief

Department: Department of Statistics

Affiliation: The University of Burdwan, Burdwan

Designation: Professor

Country: India

Rabindra Nath Das is a Professor in the Department of Statistics, The University of Burdwan, Burdwan, West Bengal, India. He holds a Ph. D., in Statistics, from The University of Burdwan, India, and Post-Doc from Seoul National University, Seoul, Korea. He has authored more than 142 research articles, and along with a research Monograph entitled- Robust Response Surfaces, Regression, and Positive Data Analyses, published from CRC Press, Taylor & Francis, Chapman & Hall. He wrote research articles on DOE, Applied Statistics, Quality & Civil Engineering, Epidemiology, Medical sciences, etc. His special area of interest is on DOE, Regression analysis, Quality Engineering and Epidemiology. He has received ‘Gopal Kanji Prize 2009’ by The Journal of Applied Statistics and Routledge publications’ for the best article published in volume 36(7), pp. 755-767. He has received certificate of appreciation for outstanding research by the Editor-In-Chief, Journal of Thyroid Science, given in the Journal Website, for the paper–Vol. 6, No. 2, pp. 1-15. He is acting as Editor, Associate Editor, Executive Editor, Editorial Board Member of more than 135 Journals in Statistics, Physical Sciences, Medical Sciences. He has acted as a Research Professor in 2018-2019 (for six months) & 2019 (for three months) in Data Science for Knowledge Creation Research Center, Statistics Department, Seoul National University, South Korea. He has been awarded Shiksharatna Award 2021 by the Govt. of West Bengal, and he has been selected as Ajou Global Fellow (AGF) by Euiho Suh, Ph.D. VP & Chair, UEMC, AJOU University, South Korea. He is the Editor-In-Chief of the Journal of ‘Econometrics and Statistics’.

Bassam Abdul Rasool Hassan

Bassam Abdul Rasool Hassan PhD

Editor-in-Chief

Department: Department of Pharmacy

Affiliation: Al-Rafidain University College, Baghdad

Designation: Senior Lecturer

Country: Iraq

Bassam Abdul Rasool Hassan holds a PhD in Clinical Pharmacy from the School of Pharmacy, Universiti Sains Malaysia (USM). He has worked as a Senior Lecturer at the Department of Pharmacy, Faculty of Medicine, University Malaya (UM) (2014–2017), and at the Department of Pharmacy Practice, Faculty of Pharmacy, Universiti Teknologi MARA (UiTM) (2017–2019). Currently, he is a Senior Lecturer at the Department of Pharmacy, AL-Rafidain University College in Baghdad, Iraq.

Editorial Members

Meng-Yao Li

Meng-Yao Li Ph.D

Editorial Member

Affiliation: Shanghai Jiao Tong University School of Medicine, Shanghai

Department: Department of Oncology

Designation: Assistant Professor

Country: China

Dr. Meng-Yao Li is currently serving as an assistant professor at Renji Hospital Affiliated to Shanghai Tong University School of Medicine. He obtained his graduate degree from the prestigious Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, under the esteemed guidance of Prof. Guo-Qiang Lin. Li has made significant contributions to various scientific publications in renowned journals such as Aggregate, Sci. China Chem., Angew. Chem. Int. Ed., Nat. Commun., Green Chem., iScience, Org. Lett., and Chem. Commun. His research output comprises more than 30 SCI papers that have garnered a total citation count of 500, resulting in a personal H-index value of 13. His research interests are investigating green synthesis, solvent-free and catalyst-free reaction; exploring drug design, synthesis, and their antitumor properties; developing and utilizing patient-derived organoid models as well as patient-derived tumor xenografts; studying drug resistance mechanisms in biliary and pancreatic tumors.

Shakeel Hoosdally

Shakeel Hoosdally PhD

Editorial Member

Affiliation: Ministry of Education and Higher Tertiary Scientific Research, Port-Louis

Department: Department of Chemistry

Designation: Head

Country: Mauritius

Dr. Shakeel Hoosdally is a medicinal chemist with over 25 years of experience in academic leadership and scientific research. He serves as Head of the Chemistry Department at the Ministry of Education and Higher Tertiary Scientific Research in Mauritius.

Dr. Hoosdally holds a Ph.D. in Pharmacology and Toxicology, an M.Sc. in Drug Design and Drug Discovery, and a Postgraduate Diploma in Medicinal Chemistry. His research focuses on computational oncology, molecular docking, and the discovery of cryptic druggable pockets, particularly targeting TP53 mutations in cancer. He has published peer-reviewed articles and book chapters in the fields of cancer therapeutics, precision pharmacology, and drug repurposing. He brings expertise in computer-aided drug design, molecular dynamics, and systems pharmacology, contributing to the development of innovative therapeutic strategies in oncology.

 

Hany Azzam

Hany Azzam PhD

Editorial Member

Affiliation: Dr Bakhsh Hospital, Jeddah

Department: Department of Clinical Pharmacy

Designation: Senior Clinical Pharmacist

Country: Egypt

Hany Azzam is a seasoned clinical pharmacist and academician with extensive experience in both hospital and university settings. Currently serving as a Senior Clinical Pharmacist at Dr. Bakhsh Hospital in Jeddah, Saudi Arabia, he specializes in optimizing drug therapy, monitoring patient outcomes, and implementing clinical pharmacy practices. He previously held academic positions at Heliopolis University in Cairo, including Lecturer and Assistant Lecturer of Clinical Pharmacy. Azzam earned his PhD in Pharmacology and Toxicology from Ain Shams University, focusing on tamoxifen resistance in breast cancer. He holds multiple advanced degrees, including Master's degrees in Clinical Pharmacy and Clinical Pharmacology, and is certified by the American Board of Pharmacotherapy (BCPS). His research contributions are published in several peer-reviewed journals, notably in the fields of oncology and pharmacotherapy.

Hao Chen

Hao Chen PhD

Editorial Member

Affiliation: Lanzhou University Second Hospital, Lanzhou

Department: Department of Gastroenterology

Designation: Professor

Country: China

Hao Chen is an accomplished surgical oncologist and academic leader, currently serving as the Director of the Cancer Center and the Science and Technology Department at the Second Hospital of Lanzhou University. He also holds multiple prestigious roles including Director of the Oncology Teaching and Research Office, Drug Clinical Trial Facility (GCP) Office, and the Gastrointestinal Cancer Center of Gansu Province. Chen earned his MBBS from Lanzhou Medical College in 2000, followed by a Master’s in General Surgery from Lanzhou University in 2003. He completed his PhD at Zhejiang University in 2008, with joint training at the University of Florida, where he later held academic positions from 2007 to 2014. His clinical expertise spans minimally invasive and robotic surgery for digestive system cancers such as gastric, liver, colorectal, and pancreatic tumors. With over 230 publications, 36 utility model patents, and supervision of nearly 70 graduate students, his academic impact is extensive. He has led or participated in over 50 significant research projects and clinical trials with funding exceeding 12 million yuan.